Evidence map›Paper›PMID 38726411›Full record

ReviewFood science & nutrition2024

Oridonin from

Muhammad Asif Ali, Noohela Khan, Ahmad Ali, Hira Akram, Noushaba Zafar, Kinza Imran, Tooba Khan, Khushbukhat Khan, Muhammad Armaghan, Marta Palma-Morales and 5 more

Abstract readReview
In one paragraph

Review in Food science & nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Canadian journal of gastroenterology & hepatology · 2025
    Article
  10. Review
  11. Oridonin fromFood science & nutrition · 2024
    Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Muhammad Asif AliDepartment of Food Science and Human Nutrition UVAS Lahore Pakistan.
Noohela KhanDepartment of Nutrition Sciences Rashid Latif Medical College Lahore Pakistan.
Ahmad AliDepartment of Food Science and Human Nutrition UVAS Lahore Pakistan.
Hira AkramDepartment of Food Science and Human Nutrition UVAS Lahore Pakistan.
Noushaba ZafarDepartment of Food Science and Human Nutrition UVAS Lahore Pakistan.
Kinza ImranDepartment of Food Science and Human Nutrition UVAS Lahore Pakistan.
Tooba KhanDepartment of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences National University of Sciences and Technology Islamabad Pakistan.
Khushbukhat KhanCancer Clinical Research Unit, Trials360 Lahore Pakistan.
Muhammad ArmaghanDepartment of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences National University of Sciences and Technology Islamabad Pakistan.
Marta Palma-MoralesDepartamento de Nutrición y Bromatología, Facultad de Farmacia Universidad de Granada Granada Spain.
Celia Rodríguez-PérezDepartamento de Nutrición y Bromatología, Facultad de Farmacia Universidad de Granada Granada Spain.
Angela Caunii"Victor Babes" University of Medicine and Pharmacy Timisoara Romania.
Monica ButnariuUniversity of Life Sciences "King Mihai I" from Timisoara Timisoara Romania.ORCID https://orcid.org/0000-0002-2032-5000
Solomon HabtemariamPharmacognosy Research & Herbal Analysis Services UK University of Greenwich Kent UK.
Javad Sharifi-RadFacultad de Medicina Universidad del Azuay Cuenca Ecuador.ORCID https://orcid.org/0000-0002-7301-8151

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer incidences are rising each year. In 2020, approximately 20 million new cancer cases and 10 million cancer-related deaths were recorded. The World Health Organization (WHO) predicts that by 2024 the incidence of cancer will increase to 30.2 million individuals annually. Considering the invasive characteristics of its diagnostic procedures and therapeutic methods side effects, scientists are searching for different solutions, including using plant-derived bioactive compounds, that could reduce the probability of cancer occurrence and make its treatment more comfortable. In this regard, oridonin (ORI), an ent-kaurane diterpenoid, naturally found in the leaves of

Indexed as

anticancer propertiescancer treatmentditerpenoidnatural compoundORI

Identifiers

PMID38726411
PMCPMC11077219

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.